Related Experiment Video

Updated: Dec 22, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

The inhibition of the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3 pathway

X X Jiao1, S Y Lin2, S X Lian3

  • 1Baoshan branch, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

Neoplasma
|May 11, 2020
PubMed

Insights

Reduced PPARγ expression and increased promoter methylation are linked to breast cancer. The PPARγ agonist pioglitazone inhibited cancer cell proliferation and migration, offering a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer remains a significant health challenge with limited therapeutic options.
  • Peroxisome proliferator-activated receptor gamma (PPARγ) functions as a tumor suppressor, with agonists showing potential in cancer inhibition.
  • The role of PPARγ and its agonists in breast cancer therapy requires further investigation.

Purpose of the Study:

  • To investigate the expression and regulation of PPARγ in breast cancer.
  • To evaluate the therapeutic potential of the PPARγ agonist pioglitazone in breast cancer models.
  • To elucidate the molecular pathways involved in pioglitazone's anti-cancer effects.

Main Methods:

  • Bioinformatic analysis of PPARγ expression using TCGA data (UALCAN).
  • Assay of PPARγ promoter methylation and gene expression regulation studies (5'-Aza, fluorescence assays).
  • In vitro assays (cell viability, scratch, transwell) and in vivo studies in a nude mice model to assess pioglitazone's effects.

Main Results:

  • PPARγ expression was significantly reduced in breast cancer tissues compared to normal tissues.
  • Increased methylation in the PPARγ promoter region correlated with decreased gene expression.
  • Pioglitazone demonstrated significant inhibition of breast cancer cell proliferation and migration in vitro and tumor growth in vivo, mediated by PPARγ and the JAK2/STAT3 pathway.

Conclusions:

  • Decreased PPARγ expression in breast cancer is associated with promoter hypermethylation.
  • Pioglitazone exhibits anti-cancer properties in breast cancer by targeting the PPARγ pathway and inhibiting the JAK2/STAT3 signaling cascade.
  • Pioglitazone represents a promising therapeutic agent for breast cancer treatment.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.0K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

770

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K